Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Adicionar filtros








Intervalo de ano
1.
Chinese journal of integrative medicine ; (12): 498-504, 2013.
Artigo em Inglês | WPRIM | ID: wpr-293252

RESUMO

<p><b>OBJECTIVE</b>To assess the efficacy and safety of Gastrosis No.1 compound in the treatment of functional dyspepsia with Spleen (Pi) and Stomach (Wei) deficiency-cold syndrome.</p><p><b>METHODS</b>A randomized, double-blind, placebo-controlled trial was performed in 5 centers. Patients with functional dyspepsia (FD) of Spleen-deficiency and qi-stagnation syndrome (162 cases) were randomly assigned to groups given Chinese herbal medicine (CHM) Gastrosis No.1 compound or placebo in a 2:1 ratio. This trial included a 4-week treatment period and a 4-week follow-up period. The outcomes were the dyspepsia symptom scores (measured by total dyspepsia symptom scale and single dyspepsia symptom scale) and syndromes of traditional Chinese medicine score (measured by traditional Chinese medicine syndrome scale). The outcomes were noted at weeks 0, 4 and 8.</p><p><b>RESULTS</b>Compared with patients in the placebo group, patients in the CHM group showed significant improvement in the dyspepsia symptom scores as rated by patients and investigators (P <0.01), and also showed improvement in syndromes of traditional Chinese medicine score (P <0.01). No serious adverse event was reported. Safety tests obtained after 4 weeks of treatment showed no abnormal values.</p><p><b>CONCLUSION</b>CHM Gastrosis No.1 compound was effective and safe in the treatment of functional dyspepsia with Spleen and Stomach deficiency-cold syndrome.</p>


Assuntos
Adulto , Feminino , Humanos , Masculino , Método Duplo-Cego , Medicamentos de Ervas Chinesas , Farmacologia , Usos Terapêuticos , Dispepsia , Tratamento Farmacológico , Placebos , Baço , Estômago , Síndrome , Resultado do Tratamento
2.
Chinese Journal of Integrated Traditional and Western Medicine ; (12): 92-94, 2006.
Artigo em Chinês | WPRIM | ID: wpr-234798

RESUMO

<p><b>OBJECTIVE</b>To explore the relationship between precancerous lesions of gastric antrum and substance P (SP) , vasoactive intestinal peptide ( VIP) , calcitonin gene-related peptide (CGRP), and the therapeutic mechanism of Zu' ai Weitai Granule (ZWG) , a TCM preparation.</p><p><b>METHODS</b>The rat model of precancerous lesions of gastric carcinoma was induced by the combined method of N-methyl N' -nitrosoguani-dine (MNNG) and mechanical injury on gastric mucosa. The pathologic morphological changes of gastric mucosa were observed after prophylactic and therapeutic administration of ZWG. In the meantime,the changes in SP, VIP and CGRP contents were determined by immunohistochemical staining.</p><p><b>RESULTS</b>The contents of SP and CGRP in gastric antrum were obviously improved in the ZWG group when compared with those in the control group (P <0. 05). There was no significant difference in VIP content between the two groups (P >0. 05).</p><p><b>CONCLUSION</b>ZWG could improve SP, VIP, and CGRP contents in rats' gastric antrum either as prophylactic administration or therapeutic administration.</p>


Assuntos
Animais , Ratos , Antineoplásicos Fitogênicos , Farmacologia , Peptídeo Relacionado com Gene de Calcitonina , Metabolismo , Carcinoma , Metabolismo , Medicamentos de Ervas Chinesas , Farmacologia , Lesões Pré-Cancerosas , Metabolismo , Antro Pilórico , Metabolismo , Neoplasias Gástricas , Metabolismo , Substância P , Metabolismo , Peptídeo Intestinal Vasoativo , Metabolismo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA